Published in FASEB J on February 17, 2012
Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov (2013) 1.74
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem (2012) 1.23
Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain (2014) 1.21
Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. Brain Behav Immun (2014) 0.97
Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. J Med Chem (2013) 0.96
Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates. J Med Chem (2013) 0.94
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. J Med Chem (2014) 0.94
Structural probing of off-target G protein-coupled receptor activities within a series of adenosine/adenine congeners. PLoS One (2014) 0.90
Potential for developing purinergic drugs for gastrointestinal diseases. Inflamm Bowel Dis (2014) 0.90
The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. J Biol Chem (2014) 0.87
Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions. ACS Med Chem Lett (2012) 0.86
Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics. Br J Pharmacol (2016) 0.84
Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy. ACS Med Chem Lett (2015) 0.84
Structure-Based Design, Synthesis by Click Chemistry and in Vivo Activity of Highly Selective A3 Adenosine Receptor Agonists. Medchemcomm (2015) 0.83
The purinergic system and glial cells: emerging costars in nociception. Biomed Res Int (2014) 0.82
Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain. J Neurosci (2015) 0.81
Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. Purinergic Signal (2015) 0.81
Rigid Adenine Nucleoside Derivatives as Novel Modulators of the Human Sodium Symporters for Dopamine and Norepinephrine. J Pharmacol Exp Ther (2016) 0.77
Peripheral Adenosine A3 Receptor Activation Causes Regulated Hypothermia in Mice That Is Dependent on Central Histamine H1 Receptors. J Pharmacol Exp Ther (2015) 0.77
John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors. Comput Struct Biotechnol J (2014) 0.76
Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor. Bioorg Med Chem Lett (2014) 0.76
Cancer and orofacial pain. Med Oral Patol Oral Cir Bucal (2016) 0.75
Metabolic mapping of A3 adenosine receptor agonist MRS5980. Biochem Pharmacol (2015) 0.75
Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain. Expert Opin Ther Pat (2017) 0.75
Caffeine as an opioid analgesic adjuvant in fibromyalgia. J Pain Res (2017) 0.75
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain (1988) 15.15
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol (1980) 6.82
A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther (1957) 6.07
The evidence for pharmacological treatment of neuropathic pain. Pain (2010) 4.35
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Glial activation: a driving force for pathological pain. Trends Neurosci (2001) 3.98
The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain (2006) 3.67
A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain (2001) 2.28
A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther (2004) 2.21
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther (2005) 2.03
Inosine reduces ischemic brain injury in rats. Stroke (2005) 1.83
Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci (1998) 1.79
Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol (2006) 1.58
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem (2005) 1.54
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett (1993) 1.51
Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. J Pharmacol Exp Ther (2006) 1.46
Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci (2004) 1.39
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol (2007) 1.38
Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol (2009) 1.35
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1998) 1.32
Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury. Am J Physiol Heart Circ Physiol (2007) 1.31
Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem (1998) 1.28
Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med (2011) 1.28
Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J Neurosci Res (2006) 1.26
Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol (2011) 1.24
The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell Immunol (2009) 1.18
Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care (2011) 1.13
Misconceptions and controversies regarding the use of opioids in cancer pain. Anticancer Drugs (1995) 1.12
The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem Biophys Res Commun (1997) 1.10
A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs (2002) 1.07
Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol (2003) 1.07
Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther (2008) 1.07
Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol (2009) 1.05
Pharmacology and therapeutic applications of A3 receptor subtype. Curr Top Med Chem (2003) 1.02
Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J Neurosci (2009) 1.01
Dual purinergic synaptic transmission in the human enteric nervous system. Am J Physiol Gastrointest Liver Physiol (2007) 1.00
Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. J Exp Clin Cancer Res (2009) 0.99
CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol (2011) 0.99
A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol (2009) 0.98
Pathophysiology and animal models of cancer-related painful peripheral neuropathy. Oncologist (2010) 0.97
Adenosine A3 receptors are located in neurons of the rat hippocampus. Neuroreport (2003) 0.95
Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur J Pharmacol (1999) 0.94
Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood (1995) 0.93
Adenosine-induced activation of esophageal nociceptors. Am J Physiol Gastrointest Liver Physiol (2010) 0.91
The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells. Neurochem Int (2009) 0.91
Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test. Anesth Analg (2005) 0.89
The influence of adenosine A3 receptor agonist: IB-MECA, on scopolamine- and MK-801-induced memory impairment. Behav Brain Res (2003) 0.89
Zinc functions as a cytotoxic agent for prostate cancer cells independent of culture and growth conditions. J Exp Ther Oncol (2010) 0.88
Activation of A(3) receptors by endogenous adenosine inhibits synaptic transmission during hypoxia in rat cortical neurons. Restor Neurol Neurosci (2003) 0.84
Allosteric modulation of purine and pyrimidine receptors. Adv Pharmacol (2011) 0.84
Synthesis and pharmacological characterization of [(125)I]MRS1898, a high-affinity, selective radioligand for the rat A(3) adenosine receptor. Purinergic Signal (2008) 0.82
Peroxynitrite-mediated nitration of peptides: characterization of the products by electrospray and combined gas chromatography-mass spectrometry. Arch Biochem Biophys (1997) 0.82
Species comparison of adenosine receptor subtypes in brain and testis. Neurochem Res (2007) 0.77
A3 receptor ligands: past, present and future trends. Curr Top Med Chem (2010) 0.77
Structure of an agonist-bound human A2A adenosine receptor. Science (2011) 6.21
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev (2006) 5.28
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature (2007) 3.78
Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med (2003) 3.71
Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc (2008) 2.80
Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med (2008) 2.70
Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol (2003) 2.59
Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci (2003) 2.37
A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med (2003) 2.24
A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther (2004) 2.21
Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem (2004) 2.15
Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res (2011) 2.06
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J Med Chem (2002) 1.97
Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood (2005) 1.84
N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. Biochem Pharmacol (2003) 1.82
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem (2002) 1.77
On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol (2003) 1.77
Structure-based discovery of A2A adenosine receptor ligands. J Med Chem (2010) 1.71
Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem (2003) 1.70
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology (2010) 1.70
Pure MnTBAP selectively scavenges peroxynitrite over superoxide: comparison of pure and commercial MnTBAP samples to MnTE-2-PyP in two models of oxidative stress injury, an SOD-specific Escherichia coli model and carrageenan-induced pleurisy. Free Radic Biol Med (2008) 1.65
Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an Escherichia coli model of septic shock: correlation with preserved circulating catecholamines. Crit Care Med (2003) 1.58
2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem (2003) 1.57
Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev (2005) 1.57
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem (2005) 1.54
Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation (2009) 1.54
Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (2010) 1.53
2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol (2002) 1.52
MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther (2005) 1.51
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol (2002) 1.49
Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta (2011) 1.46
Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. Mol Pharmacol (2003) 1.46
Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today (2011) 1.44
Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem (2002) 1.44
Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J Med Chem (2005) 1.43
Molecular Architecture of G Protein-Coupled Receptors. Drug Dev Res (1996) 1.39
Complications of open abdominal aortic surgery: the endovascular solution. Interact Cardiovasc Thorac Surg (2007) 1.39
Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. J Med Chem (2009) 1.38
Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol (2004) 1.38
Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. J Clin Invest (2007) 1.37
Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg Med Chem (2004) 1.34
Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. J Neurosci (2010) 1.34
Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury. Am J Physiol Heart Circ Physiol (2007) 1.31
Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther (2004) 1.31
Lipophilicity of potent porphyrin-based antioxidants: comparison of ortho and meta isomers of Mn(III) N-alkylpyridylporphyrins. Free Radic Biol Med (2009) 1.30
Conformational changes involved in G-protein-coupled-receptor activation. Trends Pharmacol Sci (2008) 1.29
Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. J Med Chem (2006) 1.28
Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. Am J Physiol Heart Circ Physiol (2002) 1.27
Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. J Med Chem (2002) 1.26
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. J Med Chem (2003) 1.25
Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci U S A (2004) 1.25
Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol (2004) 1.25
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor. J Med Chem (2006) 1.25
Rapid identification of functionally critical amino acids in a G protein-coupled receptor. Nat Methods (2007) 1.24
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem (2012) 1.23
A role for superoxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol (2002) 1.23
Keynote review: allosterism in membrane receptors. Drug Discov Today (2006) 1.22
"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem (2005) 1.21
Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J Neurosci (2012) 1.21
Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. Mol Pharmacol (2009) 1.20
Superoxide-mediated nitration of spinal manganese superoxide dismutase: a novel pathway in N-methyl-D-aspartate-mediated hyperalgesia. Pain (2004) 1.20
Emerging adenosine receptor agonists. Expert Opin Emerg Drugs (2007) 1.19
Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. J Med Chem (2007) 1.18
Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev (2006) 1.18
Paraffin embedding tissue samples for sectioning. CSH Protoc (2008) 1.18
The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr Eye Res (2005) 1.17
Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug Chem (2008) 1.17
Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M(3) muscarinic acetylcholine receptor. J Biol Chem (2005) 1.17
CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem Pharmacol (2005) 1.17
Structural determinants of efficacy at A3 adenosine receptors: modification of the ribose moiety. Biochem Pharmacol (2004) 1.16
Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem (2008) 1.16
Activity of Novel Adenine Nucleotide Derivatives as Agonists and Antagonists at Recombinant Rat P2X Receptors. Drug Dev Res (2000) 1.16
A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock. J Pharmacol Exp Ther (2006) 1.15
UDP is a competitive antagonist at the human P2Y14 receptor. J Pharmacol Exp Ther (2008) 1.13
Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. Bioconjug Chem (2008) 1.13
Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res (2010) 1.12
Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.12
Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. J Med Chem (2007) 1.12
P2Y6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosis. Cell Mol Neurobiol (2003) 1.11
2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. Biochem Pharmacol (2004) 1.11
Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol (2002) 1.11
Lipophilicity is a critical parameter that dominates the efficacy of metalloporphyrins in blocking the development of morphine antinociceptive tolerance through peroxynitrite-mediated pathways. Free Radic Biol Med (2008) 1.10
Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chem Commun (Camb) (2003) 1.10
Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system. J Med Chem (2009) 1.10
UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. Biochem Pharmacol (2009) 1.10
Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety. Bioorg Med Chem Lett (2005) 1.09
Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. FASEB J (2008) 1.08
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem (2008) 1.08
Expression of inducible nitric-oxide synthase and intracellular protein tyrosine nitration in vascular smooth muscle cells: role of reactive oxygen species. J Biol Chem (2003) 1.08
[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. Br J Pharmacol (2006) 1.07
Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther (2008) 1.07
Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol (2003) 1.07
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett (2008) 1.07
Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists. Bioorg Med Chem (2004) 1.07
Synthesis of ethyl (1S,2R,3S,4S,5S)-2,3-O-(isopropylidene)-4-hydroxy-bicyclo[3.1.0]hexane-carboxylate from L-ribose: a versatile chiral synthon for preparation of adenosine and P2 receptor ligands. Nucleosides Nucleotides Nucleic Acids (2008) 1.07